Novartis says meningitis vaccine performed well in large trial
Swiss drug maker Novartis AG said Tuesday that its experimental meningitis vaccine performed well in a large clinical trial and that the company expects to file it for regulatory approval in the US and Europe this year.
Novartis International AG / Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease processed and transmitted by Hugin AS.